Fuld
SEPTEMBER 23, 2024
This month, we examine the cutting-edge research strategies and tools that give businesses a competitive edge and enhance decision-making. Discover how to build early warning programs from scratch to stay ahead of the competition, leverage neuromarketing to boost engagement, and learn how healthcare researchers can utilize Fuld’s comprehensive guide to deliver more impactful research.
Drug Topics
SEPTEMBER 23, 2024
Albert Dahan, MD, PhD, discusses how cebranopadol could fit into the broader landscape of pain management therapies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
SEPTEMBER 23, 2024
The health data company Particle Health has filed an antitrust lawsuit against Epic Systems, alleging that the electronic health record vendor has used its control of patient data to thwart competition and undermine its business. The suit filed Monday in federal court in the Southern District of New York is a full-throated assault on Epic’s dominance in the market for electronic health records, charging that the privately held company has become a “behemoth” and a “mo
Drug Topics
SEPTEMBER 23, 2024
The monoclonal antibody was also approved for active non-radiographic axial spondyloarthritis and active ankylosing spondylitis.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Fierce Healthcare
SEPTEMBER 23, 2024
What began as a dispute between two health tech companies over healthcare data exchange practices has now led to a federal lawsuit alleging antitrust violations. | Venture-backed health tech company Particle Health filed an antitrust lawsuit against Epic in the Southern District of New York alleging that the electronic health records giant is trying to muscle out competition in the payer platform market.
Drug Topics
SEPTEMBER 23, 2024
LEO Pharma expects the regulatory review process to be completed in the second half of 2025.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Drug Topics
SEPTEMBER 23, 2024
Initiatives such as media campaigns and legislative rulings by the agencies have likely contributed to the decline.
STAT
SEPTEMBER 23, 2024
As the Hatch-Waxman Act approaches its 40th anniversary, it’s time to critically examine its legacy and what it actually gave us: the highest drug prices in the world. One of the main objectives of the Hatch-Waxman Act was to bring more generic drugs into the market. If viewed through that lens only, the act has been an overwhelming success.
Drug Topics
SEPTEMBER 23, 2024
Drug Topics discussed independent pharmacy advocacy and PBM reform on the state level with Miguel Rodriguez, Executive Vice President and general counsel for American Pharmacies.
STAT
SEPTEMBER 23, 2024
On Tuesday, the Department of Health and Human Services published new policies on research misconduct , which apply to research institutions receiving funding through the U.S. Public Health Service. The policies set standards that institutions must follow when investigating and potentially sanctioning researchers alleged to have engaged in research misconduct.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Drug Topics
SEPTEMBER 23, 2024
“Pharmacies are processing prescriptions, our supply chain is fully operational, and most importantly, the first patients are now receiving neffy,” said Eric Karas, CCO of ARS Pharmaceuticals.
STAT
SEPTEMBER 23, 2024
The federal watchdog at the Department of Health and Human Services issued a report on Tuesday calling for more oversight of remote patient monitoring in Medicare. The Office of Inspector General’s report called out the potential for fraud and misuse of tools like at-home blood pressure cuffs, connected scales, and continuous glucose monitors that can feed data directly to a patient’s doctor.
Drug Topics
SEPTEMBER 23, 2024
Eroxon topical gel addresses a significant unmet need for men experiencing erectile dysfunction.
Pharmacy Times
SEPTEMBER 23, 2024
Approved with 3 new indications, bimekizumab-bkzx is the first and only interleukin-17 inhibitor approved for these diseases.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
STAT
SEPTEMBER 23, 2024
The GLP-1 drug Wegovy tops the list of medications expected to be included in the next round of Medicare price negotiations, according to a paper in the Journal of Managed Care & Specialty Pharmacy. Last month, Medicare officials unveiled prices for the first 10 drugs chosen for negotiation. Now, all eyes are on which Part D drugs will be chosen for the next round of 15 drugs.
Pharmacy Times
SEPTEMBER 23, 2024
Further trials are required to examine the long-term feasibility of intravenous immunoglobulin (IVIG) for multisystem inflammatory syndrome.
STAT
SEPTEMBER 23, 2024
Two Democratic lawmakers are working to preserve health providers’ right to prescribe controlled substances via telehealth, including stimulants for ADHD and buprenorphine for opioid addiction. A new bill being drafted by Sen. Mark Warner (D-Va.) and Rep. Doris Matsui (D-Calif.) comes months before the expiration of temporary waivers first enacted by the Drug Enforcement Administration’s during the Covid-19 pandemic.
PharmaVoice
SEPTEMBER 23, 2024
A new report examines the patient reach efforts of 20 of the world’s largest pharma companies in low- and middle-income countries.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
STAT
SEPTEMBER 23, 2024
Biogen and UCB said Tuesday that an experimental drug reduced disease activity and symptoms of systemic lupus, achieving the primary goal of a placebo-controlled Phase 3 study. Detailed study results were not included in the press release issued by the companies, so how much participants benefited from the drug, called dapirolizumab pegol, won’t be known until data are presented at a medical meeting.
Pharmacy Times
SEPTEMBER 23, 2024
Event will share patient, specialty pharmacy, pharmaceutical industry and payer perspectives
Fierce Pharma
SEPTEMBER 23, 2024
Less than a year after snagging its first FDA approval in psoriasis, UCB’s blockbuster hopeful Bimzelx has picked up three more indications to add to its growing resume of inflammatory disease trea | Along with psoriasis, the biologic is now FDA approved to treat psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis.
Pharmacy Times
SEPTEMBER 23, 2024
Migraine is a chronic neurological disease characterized by throbbing or pulsating unilateral or bilateral headache that can last from hours to days.
STAT
SEPTEMBER 23, 2024
Good morning! Health care challenges like anti-microbial resistance have long created narrative tension for shows like Grey’s Anatomy. But what about an entire musical about it? Ask and ye shall receive. The wheels on the anti-pharma bus … echo GOP talking points A new, dark money group called Americans for Pharma Reform is aiming to bring awareness to what they call bad behavior by the pharmaceutical industry.
Fierce Pharma
SEPTEMBER 23, 2024
Despite being thrown off its rhythm twice already, Johnson & Johnson is making another go of its “Texas two-step” strategy to wash its hands of tens of thousands of lawsuits claiming the compan | Johnson & Johnson is making another go of its “Texas two-step” strategy to wash its hands of tens of thousands of lawsuits claiming the company’s talc products caused users to develop cancer.
STAT
SEPTEMBER 23, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! Today, we discuss a bus with anti-pharma messaging that’s traversing the country, we see the FTC file a suit against the three biggest pharmaceutical benefit managers, and more.
pharmaphorum
SEPTEMBER 23, 2024
Zevra Therapeutics' Miplyffa is first drug approved by the FDA for ultra-rare disease Niemann-Pick type C.
STAT
SEPTEMBER 23, 2024
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because — you guessed it — that oh-so familiar routine of online meetings, annoying commutes, and deadlines has predictably returned. But what can you do? The world, such as it is, somehow continues to spin no matter how hard we try to slow it down.
Fierce Pharma
SEPTEMBER 23, 2024
For trade group the Pharmaceutical Research and Manufacturers of America (PhRMA), the fight against pricing provisions in the Inflation Reduction Act isn’t over yet. | Late last week, the U.S. Court of Appeals for the Fifth Circuit reversed a previous dismissal of PhRMA’s Inflation Reduction Act (IRA) lawsuit from February, punting the complaint back to a lower Texas court.
STAT
SEPTEMBER 23, 2024
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of money in medicine. Sign up to get it in your inbox every Monday. FTC v. the Big 3 Kevin Dietsch/Getty Images The animosity between the Federal Trade Commission and pharmacy benefit managers has reached a boiling point. The FTC sued the nation’s three biggest PBMs last week, accusing them and their secretive group purchasing organizations of creating a “perver
pharmaphorum
SEPTEMBER 23, 2024
RHYTHM AI has FDA approval for a new version of its algorithm for mapping areas of the heart that are affected by atrial fibrillation
Pharmacy Times
SEPTEMBER 23, 2024
If approved, delgocitinib cream would be the first US treatment indicated for moderate to severe chronic hand eczema.
Pharmaceutical Technology
SEPTEMBER 23, 2024
The US FDA has granted approval for AstraZeneca's FluMist, a needle-free nasal spray influenza vaccine for self-administration.
Fierce Pharma
SEPTEMBER 23, 2024
After several years spent honing its robotic cell therapy manufacturing system, Multiply Labs has snared its first collaboration with a major cell therapy developer. | After several years spent building partnerships to hone its robotic cell therapy manufacturing system, Multiply Labs has snared its first collaboration with a major cell therapy developer: Legend Biotech.
Expert insights. Personalized for you.
Let's personalize your content